

SUPPLEMENTARY DATA

New natural furfural derivatives from the leaves and stems of *Pogostemon cablin*

Yuanhao Wang[†], Longzhen Ding[†], Qing Hu^{*}, and Chao Wang^{*}

SUSTech Engineering Innovation Center, School of Environmental Science and Engineering, Southern University of Science and Technology, Shenzhen 518055, China

*Corresponding author:

E-mail: huq@sustech.edu.cn (Q. Hu); Tel/Fax: (86)755-88018007;

E-mail: wangchaoshirley@sustech.edu.cn (C. Wang); Tel/Fax: (86)755-88010322

[†]These authors contributed equally to this work.

ABSTRACT

A new furfural derivative, pogoscafuran A (**1**), a new natural product, HMF levulinate (**2**), together with four known compounds (**3–6**) were isolated from an extract of the leaves and stems of *Pogostemon cablin* (Blanco) Benth. Their structures were elucidated on the basis of extensive spectroscopic analyses and single-crystal X-ray crystallography. Compound **1** was the first example of natural furfural derivative with a unique C5–C1' linkage between a molecule of furfural and 3-methyl-2-cyclopentenone moiety. The plausible biogenetic pathway for the new compound **1** was proposed. All these isolated compounds were tested for their inhibitory effects on the nitric oxide (NO) production induced by lipopolysaccharide in RAW264.7 cells, and only compound **1** exhibited weak inhibitory activity.

Keywords: *Pogostemon cablin*; Labiatae; furfural derivatives; single-crystal X-ray crystallography

List of Content

Scheme S1. Plausible biosynthetic pathway of compound **1**.

Figure S1. Key ^1H – ^1H COSY and HMBC correlations of compounds **1** and **2**.

Figure S2. X-ray crystallographic structure of compound **1**.

Figure S3. ^1H NMR (400 MHz) spectrum of compound **1** in CDCl_3 .

Figure S4. ^{13}C NMR and DEPT 135 (100 MHz) spectra of compound **1** in CDCl_3 .

Figure S5. HSQC spectrum of compound **1** in CDCl_3 .

Figure S6. HMBC spectrum of compound **1** in CDCl_3 .

Figure S7. ^1H – ^1H COSY spectrum of compound **1** in CDCl_3 .

Figure S8. HRESIMS spectrum of compound **1**.

Figure S9. ^1H NMR (400 MHz) spectrum of compound **2** in CDCl_3 .

Figure S10. ^{13}C NMR and DEPT 135 (100 MHz) spectra of compound **2** in CDCl_3 .

Figure S11. HSQC spectrum of compound **2** in CDCl_3 .

Figure S12. HMBC spectrum of compound **2** in CDCl_3 .

Figure S13. ^1H – ^1H COSY spectrum of compound **2** in CDCl_3 .

Figure S14. HRESIMS spectrum of compound **2**.

Figure S15. ^1H NMR (400 MHz) spectrum of compound **3** in CDCl_3 .

Figure S16. ^{13}C NMR (100 MHz) spectrum of compound **3** in CDCl_3 .

Figure S17. ^1H NMR (400 MHz) spectrum of compound **4** in CDCl_3 .


Figure S18. ^{13}C NMR (100 MHz) spectrum of compound **4** in CDCl_3 .

Figure S19. ^1H NMR (400 MHz) spectrum of compound **5** in CDCl_3 .

Figure S20. ^{13}C NMR (100 MHz) spectrum of compound **5** in CDCl_3 .

Figure S21. ^1H NMR (400 MHz) spectrum of compound **6** in CDCl_3 .

Figure S22. ^{13}C NMR (100 MHz) spectrum of compound **6** in CDCl_3 .



Scheme S1. Plausible biosynthetic pathway of compound **1**.




Figure S1. Key 1H - 1H COSY and HMBC correlations of compounds **1** and **2**.




Figure S2. X-ray crystallographic structure of compound **1**.




Figure S3. ^1H NMR (400 MHz) spectrum of compound **1** in CDCl_3 .




Figure S4. ^{13}C NMR and DEPT 135 (100 MHz) spectra of compound **1** in CDCl_3 .




Figure S5. HSQC spectrum of compound **1** in CDCl₃.




Figure S6. HMBC spectrum of compound **1** in CDCl₃.




Figure S7. ^1H - ^1H COSY spectrum of compound **1** in CDCl_3 .




Figure S8. HRESIMS spectrum of compound **1**.




Figure S9. ¹H NMR (400 MHz) spectrum of compound **2** in CDCl₃.




Figure S10. ¹³C NMR and DEPT 135 (100 MHz) spectra of compound **2** in CDCl₃.




Figure S11. HSQC spectrum of compound **2** in CDCl₃.




Figure S12. HMBC spectrum of compound **2** in CDCl₃.




Figure S13. ^1H – ^1H COSY spectrum of compound **2** in CDCl_3 .




Figure S14. HRESIMS spectrum of compound **2**.




Figure S15. ^1H NMR (400 MHz) spectrum of compound **3** in CDCl_3 .




Figure S16. ^{13}C NMR (100 MHz) spectrum of compound **3** in CDCl_3 .




Figure S17. ^1H NMR (400 MHz) spectrum of compound **4** in CDCl_3 .




Figure S18. ^{13}C NMR (100 MHz) spectrum of compound **4** in CDCl_3 .




Figure S19. ¹H NMR (400 MHz) spectrum of compound **5** in CDCl₃.




Figure S20. ¹³C NMR (100 MHz) spectrum of compound **5** in CDCl₃.




Figure S21. ¹H NMR (400 MHz) spectrum of compound **6** in CDCl₃.




Figure S22. ¹³C NMR (100 MHz) spectrum of compound **6** in CDCl₃.